Active substanceNitcheamideNitcheamide
Similar drugsTo uncover
  • Cordiamine
    drops inwards 
  • Cordiamine
    drops inwards 
  • Cordiamine
    solution for injections 
    ELLARA, LTD.     Russia
  • Cordiamine
    drops inwards 
  • Cordiamine
    drops inwards 
  • Cordiamine
    solution for injections 
  • Cordiamine
    solution for injections 
  • Cordiamine
    solution for injections 
    BIOSINTEZ, PAO     Russia
  • Cordiamine
    solution for injections 
    DALHIMFARM, OJSC     Russia
  • Cordiamine
    solution for injections 
    ESKOM NPK, OAO     Russia
  • Cordiamine
    drops inwards 
  • Cordiamine
    solution for injections 
    ORGANICS, JSC     Russia
  • Cordiamine
    solution for injections 
  • Cordiamin-Darnitsa
    solution for injections 
  • Nitakamid-Eskom
    solution w / m in / in PC 
    ESKOM NPK, OAO     Russia
  • Dosage form: & nbspinjection
    Composition:

    Diethylamide of nicotinic acid - 250 g.

    Water for Injection - up to 1 liter.

    Description:Transparent colorless or slightly colored liquid with a peculiar smell.
    Pharmacotherapeutic group:Analeptic remedy
    ATX: & nbsp

    R.07.A.B   Respiratory stimulants

    R.07.A.B.02   Nitcheamide

    Pharmacodynamics:

    Has an analeptic effect. Stimulates the central nervous system: it has an exciting effect on the vasomotor center of the medulla oblongata (especially when the center is oppressed), which leads to an indirect increase in systemic blood pressure. Excites the respiratory center due to the stimulating effect on the chemoreceptors of the sinocarotid reflexogenic zone, which leads to an increase in the frequency and depth of the respiratory movements. The drug has no direct stimulating effect on the heart and a direct stimulating vasoconstrictor effect.

    Pharmacokinetics:Well absorbed in any route of administration. It is subject to rapid biotransformation in the liver with the formation of inactive metabolites, excreted mainly by the kidneys.
    Indications:Collapse, shock conditions during surgical operations and in the postoperative period, cardiac disorders, decreased vascular tone, weakened breathing in infectious diseases and during recovery, asphyxia of newborns, poisoning with narcotic, hypnotics and analgesics.
    Contraindications:

    Hypersensitivity, epilepsy, seizures of tonic-clonic seizures in the anamnesis, hyperthermia in children, pregnancy, lactation.

    Pregnancy and lactation:
    There are no reliable data on the safety of the drug during pregnancy and during breastfeeding. It is not recommended to use the drug during pregnancy and during breastfeeding.
    Dosing and Administration:

    Adults are injected subcutaneously, intramuscularly and intravenously at a dose of 1 - 2 ml 1 - 3 times a day; Children - subcutaneously, depending on age, in a dose of 0.1 - 0.75 ml. Intravenous administration is slow.

    When intoxication drugs, hypnotics, analgesics, adults intravenously (can be subcutaneously or intramuscularly) inject 3 - 5 ml of the drug.

    Since subcutaneous and intramuscular injections of cordiamine are painful, novocaine (1 ml of a 0.5% solution) is pre-injected at the injection site to reduce pain, depending on the situation.

    Higher doses for adults subcutaneously: single - 2 ml, daily - 6 ml. The highest single dose for subcutaneous and intravenous administration for drug poisoning is 5 ml.

    Side effects:

    Anxiety, anxiety, muscle twitching (starting with the circular muscles of the mouth), tonic-clonic convulsions, allergic reactions, itching of the skin, facial hyperemia, vomiting, disturbance of the heart rhythm, infiltration and soreness at the injection site.

    Overdose:Tonic-clonic convulsions.
    Interaction:

    The convulsive effect of Cordiamin strengthens reserpine, the exciting effect on the respiratory center is eliminated by means for anesthesia, the action of the drug weakens PASK and saluside, aminazine and other phenothiazine derivatives lead to an attenuation of the analeptic effect and convulsive effect.

    Enhances the effects of psychostimulants and antidepressants. Reduces the effects of narcotic analgesics, hypnotics, neuroleptics, tranquilizers, anticonvulsants.

    Effect on the ability to drive transp. cf. and fur:
    For the duration of treatment with the drug should refrain from driving and other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
    Form release / dosage:

    Solution for injection 250 mg / ml.

    Packaging:

    1 ml, 2 ml in ampoules.

    10 ampoules in a box of cardboard with corrugated paper partitions.

    By 5 ampoules in a contoured cell pack of a polyvinyl chloride film.

    By 1, 2, 3. 4, 5 contour mesh packages in a pack of cardboard.

    In each pack, the box is attached instruction for use, ampoule knife or scarifier ampoule.

    For hospitals: 50 or 100 contour mesh packages in a cardboard box or cardboard corrugated with application instructions, but with ampoule or scarifier knives ampoule in number equal to the number of contoured cell packs.

    At packing of ampoules with a ring of a break, a point and an internal cutter the ampoule knife or scarifier ampoule does not put.

    Storage conditions:

    In the dark place at a temperature of ns above 25 ° C.

    Keep out of the reach of children.

    Shelf life:

    3 years. Do not use after the time specified on the package.

    Terms of leave from pharmacies:On prescription
    Registration number:P N003732 / 01
    Date of registration:30.06.2009 / 18.05.2016
    Expiration Date:Unlimited
    The owner of the registration certificate:BIOSINTEZ, PAO BIOSINTEZ, PAO Russia
    Manufacturer: & nbsp
    Information update date: & nbsp23.11.2017
    Illustrated instructions
      Instructions
      Up